Prognostic value of sST2 added to BNP in acute heart failure with preserved or reduced ejection fraction

go back to reference Braunwald E (2008) Biomarkers in heart failure. N Engl J Med 358(20):2148–2159CrossRefPubMed Braunwald E (2008) Biomarkers in heart failure. N Engl J Med 358(20):2148–2159CrossRefPubMed

go back to reference Maisel A, Mueller C, Adams K Jr, Anker SD, Aspromonte N, Cleland JG, Cohen-Solal A, Dahlstrom U, DeMaria A, Di Somma S, Filippatos GS, Fonarow GC, Jourdain P, Komajda M, Liu PP, McDonagh T, McDonald K, Mebazaa A, Nieminen MS, Peacock WF, Tubaro M, Valle R, Vanderhyden M, Yancy CW, Zannad F, Braunwald E (2008) State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 10(9):824–839CrossRefPubMed Maisel A, Mueller C, Adams K Jr, Anker SD, Aspromonte N, Cleland JG, Cohen-Solal A, Dahlstrom U, DeMaria A, Di Somma S, Filippatos GS, Fonarow GC, Jourdain P, Komajda M, Liu PP, McDonagh T, McDonald K, Mebazaa A, Nieminen MS, Peacock WF, Tubaro M, Valle R, Vanderhyden M, Yancy CW, Zannad F, Braunwald E (2008) State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 10(9):824–839CrossRefPubMed

go back to reference McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, McDonagh T, Sechtem U, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P (2012) ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 14:803–869CrossRefPubMed McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, McDonagh T, Sechtem U, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P (2012) ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 14:803–869CrossRefPubMed

go back to reference Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL (2013) American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 62(16):e147–e239CrossRefPubMed Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL (2013) American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 62(16):e147–e239CrossRefPubMed

go back to reference Dale M, Nicklin MJ (1999) Interleukin-1 receptor cluster: gene organization of IL1R2, IL1R1, IL1RL2 (IL-1 Rrp2), IL1RL1 (T1/ST2), and IL18R1 (IL-1Rrp) on human chromosome 2q. Genomics 57(1):177–179CrossRefPubMed Dale M, Nicklin MJ (1999) Interleukin-1 receptor cluster: gene organization of IL1R2, IL1R1, IL1RL2 (IL-1 Rrp2), IL1RL1 (T1/ST2), and IL18R1 (IL-1Rrp) on human chromosome 2q. Genomics 57(1):177–179CrossRefPubMed

go back to reference Iwahana H, Yanagisawa K, Ito-Kosaka A, Kuroiwa K, Tago K, Komatsu N, Katashima R, Itakura M, Tominaga S (1999) Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells. Eur J Biochem 264(2):397–406CrossRefPubMed Iwahana H, Yanagisawa K, Ito-Kosaka A, Kuroiwa K, Tago K, Komatsu N, Katashima R, Itakura M, Tominaga S (1999) Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells. Eur J Biochem 264(2):397–406CrossRefPubMed

go back to reference Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zurawski G, Moshrefi M, Qin J, Li X, Gorman DM, Bazan JF, Kastelein RA (2005) IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23(5):479–490CrossRefPubMed Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zurawski G, Moshrefi M, Qin J, Li X, Gorman DM, Bazan JF, Kastelein RA (2005) IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23(5):479–490CrossRefPubMed

go back to reference Weinberg EO, Shimpo M, De Keulenaer GW, MacGillivray C, Tominaga S, Solomon SD, Rouleau JL, Lee RT (2002) Expression and regulation of ST2, an interleukin-1 receptor family member in cardiomyocytes and myocardial infarction. Circulation 106(23):2961–2966CrossRefPubMedCentralPubMed Weinberg EO, Shimpo M, De Keulenaer GW, MacGillivray C, Tominaga S, Solomon SD, Rouleau JL, Lee RT (2002) Expression and regulation of ST2, an interleukin-1 receptor family member in cardiomyocytes and myocardial infarction. Circulation 106(23):2961–2966CrossRefPubMedCentralPubMed

go back to reference Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT (2007) IL-33 and ST2 comprise a critical biochemically induced and cardioprotective signaling system. J Clin Invest 117(6):1538–1549CrossRefPubMedCentralPubMed Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT (2007) IL-33 and ST2 comprise a critical biochemically induced and cardioprotective signaling system. J Clin Invest 117(6):1538–1549CrossRefPubMedCentralPubMed

go back to reference Seki K, Sanada S, Kudinova AY, Steinhauser ML, Handa V, Gannon J, Lee RT (2009) Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail 2(6):684–691CrossRefPubMed Seki K, Sanada S, Kudinova AY, Steinhauser ML, Handa V, Gannon J, Lee RT (2009) Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail 2(6):684–691CrossRefPubMed

go back to reference Mueller T, Dieplinger B, Gegenhuber A, Poelz W, Pacher R, Haltmayer M (2008) Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin Chem 54(4):752–756CrossRefPubMed Mueller T, Dieplinger B, Gegenhuber A, Poelz W, Pacher R, Haltmayer M (2008) Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin Chem 54(4):752–756CrossRefPubMed

go back to reference Henry-Okafor Q, Collins SP, Jenkins CA, Miller KF, Maron DJ, Naftilan AJ, Weintraub N, Fermann GJ, McPherson J, Menon S, Sawyer DB, Storrow AB (2012) Soluble ST2 as a diagnostic and prognostic marker for acute heart failure syndromes. Open Biomark J 2012(5):1–8CrossRefPubMedCentralPubMed Henry-Okafor Q, Collins SP, Jenkins CA, Miller KF, Maron DJ, Naftilan AJ, Weintraub N, Fermann GJ, McPherson J, Menon S, Sawyer DB, Storrow AB (2012) Soluble ST2 as a diagnostic and prognostic marker for acute heart failure syndromes. Open Biomark J 2012(5):1–8CrossRefPubMedCentralPubMed

go back to reference Lassus J, Gayat E, Mueller C, Peacock WF, Spinar J, Harjola VP, van Kimmenade R, Pathak A, Mueller T, Disomma S, Metra M, Pascual-Figal D, Laribi S, Logeart D, Nouira S, Sato N, Potocki M, Parenica J, Collet C, Cohen-Solal A, Januzzi JL Jr (2013) Mebazaa A; GREAT-Network. Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: the Multinational Observational Cohort on Acute Heart Failure (MOCA) study. Int J Cardiol 168(3):2186–2194CrossRefPubMed Lassus J, Gayat E, Mueller C, Peacock WF, Spinar J, Harjola VP, van Kimmenade R, Pathak A, Mueller T, Disomma S, Metra M, Pascual-Figal D, Laribi S, Logeart D, Nouira S, Sato N, Potocki M, Parenica J, Collet C, Cohen-Solal A, Januzzi JL Jr (2013) Mebazaa A; GREAT-Network. Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: the Multinational Observational Cohort on Acute Heart Failure (MOCA) study. Int J Cardiol 168(3):2186–2194CrossRefPubMed

go back to reference Bishu K, Redfield MM (2013) Acute heart failure with preserved ejection fraction: unique patient characteristics and targets for therapy. Curr Heart Fail Rep 10(3):190–197CrossRefPubMed Bishu K, Redfield MM (2013) Acute heart failure with preserved ejection fraction: unique patient characteristics and targets for therapy. Curr Heart Fail Rep 10(3):190–197CrossRefPubMed

go back to reference Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, Vasan RS (2008) Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27(2):157–172CrossRefPubMed Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, Vasan RS (2008) Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27(2):157–172CrossRefPubMed

go back to reference Blair JE, Zannad F, Konstam MA, Cook T, Traver B, Burnett JC Jr, Grinfeld L, Krasa H, Maggioni AP, Orlandi C, Swedberg K, Udelson JE, Zimmer C, Gheorghiade C (2008) EVEREST Investigators. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure: results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: outcome Study with Tolvaptan) program. J Am Coll Cardiol 52(20):1640–1648CrossRefPubMed Blair JE, Zannad F, Konstam MA, Cook T, Traver B, Burnett JC Jr, Grinfeld L, Krasa H, Maggioni AP, Orlandi C, Swedberg K, Udelson JE, Zimmer C, Gheorghiade C (2008) EVEREST Investigators. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure: results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: outcome Study with Tolvaptan) program. J Am Coll Cardiol 52(20):1640–1648CrossRefPubMed

go back to reference Manzano-Fernández S, Mueller T, Pascual-Figal D, Truong QA, Januzzi JL (2011) Usefulness of soluble concentrations on interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am J Cardiol 107(2):259–267CrossRefPubMedCentralPubMed Manzano-Fernández S, Mueller T, Pascual-Figal D, Truong QA, Januzzi JL (2011) Usefulness of soluble concentrations on interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am J Cardiol 107(2):259–267CrossRefPubMedCentralPubMed

go back to reference Kossaify A, Garcia A, Succar S, Ibrahim A, Moussallem N, Kossaify M (2013) Grollier G; STAR-P Consortium. Perspectives on the value of biomarkers in acute cardiac care and implications for strategic management. Biomark Insights. 3(8):115–126CrossRef Kossaify A, Garcia A, Succar S, Ibrahim A, Moussallem N, Kossaify M (2013) Grollier G; STAR-P Consortium. Perspectives on the value of biomarkers in acute cardiac care and implications for strategic management. Biomark Insights. 3(8):115–126CrossRef

go back to reference Lee DS, Vasan RS (2005) Novel markers for heart failure diagnosis and prognosis. Curr Opin Cardiol 20(3):201–210CrossRefPubMed Lee DS, Vasan RS (2005) Novel markers for heart failure diagnosis and prognosis. Curr Opin Cardiol 20(3):201–210CrossRefPubMed

go back to reference Gaggin HK, Januzzi JL Jr (2013) Biomarkers and diagnostics in heart failure. Biochim Biophys Acta 1832(12):2442–2450CrossRefPubMed Gaggin HK, Januzzi JL Jr (2013) Biomarkers and diagnostics in heart failure. Biochim Biophys Acta 1832(12):2442–2450CrossRefPubMed

go back to reference Doust JA, Pietrzak E, Dobson A, Glasziou P (2005) How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure; systematic review. BMJ 330(7492):625CrossRefPubMedCentralPubMed Doust JA, Pietrzak E, Dobson A, Glasziou P (2005) How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure; systematic review. BMJ 330(7492):625CrossRefPubMedCentralPubMed

go back to reference Felker GM, Hasselblad V, Hernandez AF, O’Connor CM (2009) Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J 158(3):422–430CrossRefPubMed Felker GM, Hasselblad V, Hernandez AF, O’Connor CM (2009) Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J 158(3):422–430CrossRefPubMed

go back to reference Dieplinger B, Januzzi JL Jr, Steinmair M, Gabriel C, Poelz W, Haltmayer M, Mueller T (2009) Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma—the Presage ST2 assay. Clin Chim Acta 409(1–2):33–40CrossRefPubMed Dieplinger B, Januzzi JL Jr, Steinmair M, Gabriel C, Poelz W, Haltmayer M, Mueller T (2009) Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma—the Presage ST2 assay. Clin Chim Acta 409(1–2):33–40CrossRefPubMed

go back to reference Fonarow GC, Peacock WF, Phillips CO, Givertz MM, Lopatin M (2007) ADHERE Scientific Advisory Committee and Investigators. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol 49(19):1943–1950CrossRefPubMed Fonarow GC, Peacock WF, Phillips CO, Givertz MM, Lopatin M (2007) ADHERE Scientific Advisory Committee and Investigators. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol 49(19):1943–1950CrossRefPubMed

go back to reference Kociol RD, Horton JR, Fonarow GC, Reyes EM, Shaw LK, O’Connor CM, Felker GM, Hernandez AF (2011) Admission, discharge, or change in B-type natriuretic peptide and long-term outcomes: data from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) linked to Medicare claims. Circ Heart Fail 4(5):628–636CrossRefPubMedCentralPubMed Kociol RD, Horton JR, Fonarow GC, Reyes EM, Shaw LK, O’Connor CM, Felker GM, Hernandez AF (2011) Admission, discharge, or change in B-type natriuretic peptide and long-term outcomes: data from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) linked to Medicare claims. Circ Heart Fail 4(5):628–636CrossRefPubMedCentralPubMed

go back to reference Januzzi JL Jr, Peacock WF, Maisel AS, Chae CU, Jesse RL, Baggish AL, O’Donoghue M, Sakhuja R, Chen AA, van Kimmenade RR, Lewandrowski KB, Lloyd-Jones DM, Wu AH (2007) Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol 50(7):607–613CrossRefPubMed Januzzi JL Jr, Peacock WF, Maisel AS, Chae CU, Jesse RL, Baggish AL, O’Donoghue M, Sakhuja R, Chen AA, van Kimmenade RR, Lewandrowski KB, Lloyd-Jones DM, Wu AH (2007) Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol 50(7):607–613CrossRefPubMed

go back to reference Rose-Jones LJ, Rommel JJ (2014) Chang PP. Heart failure with preserved ejection fraction: an ongoing enigma. Cardiol Clin 32(1):151–161CrossRefPubMed Rose-Jones LJ, Rommel JJ (2014) Chang PP. Heart failure with preserved ejection fraction: an ongoing enigma. Cardiol Clin 32(1):151–161CrossRefPubMed

go back to reference Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM (2006) Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355(3):251–259CrossRefPubMed Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM (2006) Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355(3):251–259CrossRefPubMed

go back to reference Steinberg BA, Zhao X, Heidenreich PA, Peterson ED, Bhatt DL, Cannon CP, Hernandez AF (2012) Fonarow GC; Get With the Guidelines Scientific Advisory Committee and Investigators. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies and outcomes. Circulation 126(1):65–75CrossRefPubMed Steinberg BA, Zhao X, Heidenreich PA, Peterson ED, Bhatt DL, Cannon CP, Hernandez AF (2012) Fonarow GC; Get With the Guidelines Scientific Advisory Committee and Investigators. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies and outcomes. Circulation 126(1):65–75CrossRefPubMed

go back to reference Pascual-Figal DA, Manzano-Fernández S, Boronat M, Casas T, Garrido IP, Bonaque JC, Pastor-Perez F, Valdés M, Januzzi JL (2011) Soluble ST2, high sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. Eur J Heart Fail 13(7):718–725CrossRefPubMed Pascual-Figal DA, Manzano-Fernández S, Boronat M, Casas T, Garrido IP, Bonaque JC, Pastor-Perez F, Valdés M, Januzzi JL (2011) Soluble ST2, high sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. Eur J Heart Fail 13(7):718–725CrossRefPubMed

go back to reference Manzano-Fernández S, Januzzi JL, Pastor-Pérez FJ, Bonaque-González JC, Boronat-Garcia M, Pascual-Figal DA, Montalban-Larrea S, Navarro-Peñalver M, Andreu-Cayuelas JM, Valdés M (2012) Serial monitoring of soluble interleukin family member ST2 in patients with acutely decompensated heart failure. Cardiology 122(3):158–166CrossRefPubMed Manzano-Fernández S, Januzzi JL, Pastor-Pérez FJ, Bonaque-González JC, Boronat-Garcia M, Pascual-Figal DA, Montalban-Larrea S, Navarro-Peñalver M, Andreu-Cayuelas JM, Valdés M (2012) Serial monitoring of soluble interleukin family member ST2 in patients with acutely decompensated heart failure. Cardiology 122(3):158–166CrossRefPubMed

go back to reference Breidthardt T, Balmelli C, Twerenbold R, Mosimann T, Espinola J, Haaf P, Thalmann G, Moehring B, Mueller M, Meller B, Reichlin T, Murray K, Ziller R, Benkert P, Osswald S, Mueller C (2013) Heart failure therapy-induced early ST2 changes may offer long-term therapy guidance. J Card Fail 19(12):821–828CrossRefPubMed Breidthardt T, Balmelli C, Twerenbold R, Mosimann T, Espinola J, Haaf P, Thalmann G, Moehring B, Mueller M, Meller B, Reichlin T, Murray K, Ziller R, Benkert P, Osswald S, Mueller C (2013) Heart failure therapy-induced early ST2 changes may offer long-term therapy guidance. J Card Fail 19(12):821–828CrossRefPubMed